



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Demo Report

Report Issued 11/02/2015 07:08
Last Report Issued 07/17/2015 12:28

88888
Clinical Example Report
Attn: IT Department
200 Welsh Road
Horsham, PA 19044-2208

Patient Name 1815SP
Patient ID 1815SP
Chain 15001779
Age Not Given **DOB** Not Given
Gender Not Given
Workorder 15001779
Received 07/17/2015 12:23

Sample ID 15001779-001
Matrix Serum or Plasma
Patient Name 1815SP
Patient ID 1815SP
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

| Analysis and Comments | Result | Units | Reporting Limit | Notes |
|-----------------------|--------|-------|-----------------|-------|
|-----------------------|--------|-------|-----------------|-------|

1815SP Doxazosin, Serum/Plasma

Analysis by High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

| | | | | |
|----------------------|---------------|-------|-----|--|
| Doxazosin | None Detected | ng/mL | 2.0 | |
| Synonym(s): Cardura® | | | | |

A group of 10 adult hypertensive patients given daily 1, 2, 4 or 8 mg normal-release doses attained steady-state plasma concentrations averaging 19, 42, 79 and 101 ng/mL, respectively, at 1.7-2.7 hours post-dose.